top of page

Arcellx's CEO on Friday's #ASH23 topline release and his take on the BCMA field

Rami Elghandour compares Arcellx's estimated 28 month PFS to Carvykti, gives his take on the recent FDA notice about CAR-T, and highlights Kite's recent re-up of their partnership.


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page